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Abstract 
Purpose of review-  The innate immune system is essential in the protection against microbial 
infection and facilitating tissue repair mechanisms.  During these stresses, the maintenance of 
innate immune cell numbers through stress-induced or emergency hematopoiesis is key for our 
survival.  One major mechanism to recognize danger signals is through the activation of toll-like 
receptors on the surface of hematopoietic cells, including hematopoietic stem (HSC) and 
progenitor (HPC) cells, and non-hematopoietic cells, which recognize pathogen-derived or 
damaged-induced compounds and can influence the emergency hematopoietic response.  This 
review explores how direct pathogen-sensing by HSC/HPC regulates hematopoiesis, and the 
positive and negative consequences of these signals. 
 
Recent findings-  Recent studies have highlighted new roles for toll-like receptors in regulating 
HSC and HPC differentiation to innate immune cells of both myeloid and lymphoid origin and 
augmenting HSC and HPC migration capabilities.  Most interestingly, new insights as to how 
acute versus chronic stimulation of toll-like receptor signaling regulates HSC and HPC function 
has been explored. 
 
Summary-  Recent evidence suggests that toll-like receptors may play an important role in 
many inflammation-associated diseases.  This suggests a possible use for toll-like receptor 
agonists or antagonists as potential therapeutics.  Understanding the direct effects of toll-like 
receptor signaling by HSC and HPC may help regulate inflammatory/danger signal-driven 
emergency hematopoiesis. 
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Introduction 
Hematopoietic stem cells (HSCs) are in low frequency within the bone marrow (BM) and 
have multi-lineage differentiation potential as well as the ability for life-long self-renewal 
potential [1, 2]. Long-term (LT)-HSCs are retained in a BM microenvironment that promotes 
their survival and maintains them in a non-cycling state [3, 4].  Thus, when there is a demand for 
more mature immune cells following infection, blood loss or tissue repair, the BM has the 
required pool of HSCs and hematopoietic progenitor cells (HPC) needed to ramp up production 
of replacement mature hematopoietic cells. This stress-induced increase in production of 
mature immune cells has been dubbed emergency hematopoiesis.  How the hematopoietic 
system recognizes when to switch gears from normal, steady-state production to emergency 
hematopoiesis is driven by many factors such as pathogen-sensing (either directly by the 
HSC/HPC or indirectly by mature hematopoietic or other non-hematopoietic cells), 
cytokine/growth factor production, or other ‘danger’ signals (e.g. ROS production) and can vary 
greatly depending on the type of infection, site of injury, and duration of inflammatory response. 
How mature hematopoietic and non-hematopoietic cells regulate emergency hematopoiesis by 
external cues such as cytokine/growth factor production has been extensively reviewed [5**, 6]. 
Therefore, in this review the focus is on how immune cell numbers are regulated under 
emergency conditions via direct pathogen-sensing by HSCs and HPCs, and positive and 
negative consequences of these signals.   
 
Recognizing danger and/or infection 
In order to induce emergency hematopoiesis the hematopoietic system must first 
recognize that a stress event has taken place.  Toll-like receptors (TLRs; a type of pattern 
recognition receptor) recognize pathogen-associated molecular patterns (PAMPs) [7, 8].  TLRs 
are expressed on cells of hematopoietic origin (e.g. dendritic cells, macrophages, lymphocytes, 
HSCs, and HPCs) as well as non-hematopoietic cells (e.g. endothelial and mesenchymal stem 
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cells) [9-14]. Some TLRs are localized to the plasma membrane (e.g. TLR1, TLR2, TLR4, TLR5, 
TLR6, and TLR11) while others are found in endosomes (e.g. TLR3, TLR7, TLR8, and TLR9) 
with most acting as homodimers with the exception of TLR2 which heterodimerizes with TLR1 
or TLR6 [11, 15, 16]. The ligands for TLRs, PAMPs, are unique to groups of related 
microorganisms, e.g. lipopolysaccharide (LPS) found in bacteria cell walls or viral single-
stranded RNA, that are not associated with normal host cells.  In addition to recognizing 
pathogen-associated danger signals, TLRs can also recognize injury or tissue repair danger-
associated molecular patterns (DAMPs) [17].  DAMPs (e.g. HMGB1 and ATP) are cell-derived 
molecules that are normally expressed by cells undergoing necrosis that can trigger an innate 
immune response.  
Once TLRs recognize PAMPs or DAMPS, a signaling cascade involving myeloid 
differentiation primary response gene 88 (MyD88) recruitment is followed by complex formation 
with the serine-threonine kinase (IRAK) family members, leading to nuclear factor k-light chain-
enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) pathway 
activation resulting in pro-inflammatory cytokine (e.g. IL-1, IL-6, IL-8 and TNFα) production [11, 
18-20]. However, there are exceptions such as TLR3 signaling which is MyD88-independent, 
instead depending on the TIR-domain-containing adaptor inducing interferon-B (TRIF) pathway 
which activates interferon regulatory factor-3 (IRF3) leading to production of type 1 interferons 
[21-23].  TRIF signaling can also lead to MyD88-independent activation of NF-κB and MAPK.  
TLR4, one of the most thoroughly investigated TLRs, utilizes both MyD88- and TRIF-dependent 
signaling pathways [24]. 
 
Direct recognition of danger by hematopoietic stem and progenitor cells 
Evidence that danger signals can trigger emergency hematopoiesis in vivo is strong as 
demonstrated by the fact that direct injection of PAMPs and DAMPs (e.g. LPS) and/or infecting 
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mice with pathogens (e.g. Candida albicans or Staphylococcus aureus) can increase HSC 
proliferation and skew differentiation toward increased myeloid cell (e.g. neutrophil and 
macrophage) production in a TLR-dependent manner often at the expense of lymphopoiesis 
and erythropoiesis [25-30].  However, administration of systemic TLR agonists or the use of 
infection models such as those stated above do not address the direct role of TLRs within HSC 
and HPC populations. To test if TLR agonists can directly stimulate HSCs/HPCs, lineage 
marker negative, stem cell antigen positive-1, c-kit positive BM cells from wild type mice were 
transplanted into lethally irradiated TLR2, TLR4 or MyD88 knockout mice and then immediately 
exposed in vivo to soluble TLR ligands Pam3CSK4 (a TLR2 agonist), LPS (a TLR4 agonist) or 
CpG oligodeoxynucleotide (ODN; a TLR9 agonists that is dependent on MyD88 signaling) 
respectively. Transplanted HSCs and HPCs in response to these TLR ligands differentiated 
preferentially to macrophages demonstrating that TLR signaling directly from the HSC/HPC 
compartment can regulate specific blood cell production [29]. 
TLRs are expressed on HSCs and HPCs both in mice and humans and have been 
shown both in vitro and in vivo to affect HSC/HPC functions [12, 31-34]. Both highly 
phenotypically-defined LT-HSC populations and more broadly-defined HSC/HPC populations 
express both TLR2 and TLR4. When purified mouse LT-HSCs (sorted using SLAM markers) 
were stimulated directly with LPS, the TLR4/NF-κB axis was activated [35].  In vitro stimulation 
of less strictly defined HSC/HPC populations with Pam3CSK4 or LPS has also been shown to 
drive myeloid differentiation in a MyD88-dependent manner [13, 25-29, 33, 35-38]. Further 
studies utilizing HSCs/HPCs demonstrated that TLR4 signaling can also occur through a TRIF-
dependent pathway, ultimately leading to activation of NF-κB and/or IRF transcription factors 
[8]. Stimulation of human CD34+ BM cells with small interfering RNAs and R848 (specific 
ligands for TLR7 and TLR8) resulted in increased IL-1β, IL-6, IL-8, TNF-α, and GM-CSF 
production as well as inducing these cells to differentiate into macrophages and monocytic 
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dendritic precursors that expressed CD13, CD14 and/or CD11c markers [34] suggesting that 
TLR7 and TLR8 may also directly influence HSCs and/or HPCs. Supporting these findings, 
TLR7-mediated stimulation of common myeloid progenitors (CMPs), synergistically with type 1 
interferons, promoted monocyte/macrophage differentiation. Interestingly, this was through an 
mTOR/PI3K-dependent pathway [39].  These findings suggest that HSCs and HPCs can directly 
signal through TLRs driving myeloid differentiation, indicting that HSCs/HPCs themselves can 
act as pathogen sensors.  
However, these findings do not necessarily indicate whether the triggering of emergency 
hematopoiesis (especially skewing towards increased production of mature myeloid cells) is 
through the direct regulation of transcription factors that lead to the differentiation of these 
mature cell populations (an autocrine effect), by the production of cytokines and/or growth 
factors that promote these pathways (a paracrine effect), or both.  Further work to differentiate 
the importance of the autocrine and paracrine TLR signaling effects on HSCs and HPCs needs 
to be performed. It is becoming clearer, however, that HSC/HPC populations may be very 
important contributors to the pro-inflammatory cytokine and growth factor milieu following TLR 
stimulation. The stimulation of HSCs/HPCs, specifically short-term (ST)-HSCs and multipotent 
progenitors (MPPs), with various bacterial products resulted in production of a diverse cytokine 
milieu through NF-κB signaling [35].  In particular HSCs/HPCs produced large quantities of IL-6 
which is known to drive myeloid differentiation and HSC/HPC proliferation.  Interestingly, 
cytokine production by ST-HSC and MPP following TLR-stimulation often trumped mature 
immune cell production of cytokines following stimulation with the same doses of TLR agonist 
[35]. 
Stimulation of TLRs using PAMPs has also been demonstrated to change chemokine 
receptor expression on the surface of HSC/HPC and the ability of these cells to be retained 
within the BM [12, 40, 41]. Following a stress event, the appearance of immature myeloid 
precursor cells and other earlier progenitor cells often occurs in the peripheral blood (PB).  This 
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is referred to as a PB left shift [5**]. Upon stimulation of TLRs, common dendritic cell 
progenitors (CDPs) down-regulate expression of CXCR4 (a required chemokine receptor for 
CDP retention within the BM) and up-regulate the expression of CCR7 (a chemokine receptor 
required for CDPs to enter preferentially into inflamed lymph nodes) [12].  These findings 
suggest that TLR signaling in dendritic cell progenitors allows for dendritic cell homeostasis at 
sites of inflammation.  Recently it was found that injecting a low dose of zymosan (a TLR2 
agonist) into the peritoneal cavity of mice resulted in increased numbers of innate lymphoid 
cells, a phenomena dependent on the in situ differentiation of BM-derived HPCs and innate 
lymphoid cell precursors [42**].  This suggests that TLR signaling may play a role in the 
migration and differentiation of innate lymphoid cells and their progenitors/precursors. It is 
important to note, however, that induction of HSC/HPC migration by TLR signaling is not 
straight forward. Interestingly, MyD88 knockout mice injected with LPS and zymosan 
demonstrated normal HSC/HPC migration into the PB, similar to that of wild type controls, 
suggesting that another factor may influence the migration of these populations into the blood 
[40].   
 
Complicated interactions between granulocyte-colony stimulating factor (G-CSF) and 
TLRs in HSCs/HPCs 
G-CSF is thought to be one of the principle cytokines involved in regulating 
granulopoiesis under steady-state conditions and following many different stress events 
including infection [43-45].  One way G-CSF regulates granulopoiesis is by inducing 
commitment of MPPs down the myeloid lineage [46]. G-CSF and G-CSF receptor-deficient 
animals exhibit severe neutropenia (a condition when there is reduced neutrophil numbers in 
the blood) [47, 48] which correlates with the fact that mice that are deficient in G-CSF receptor 
have increased numbers of common lymphoid progenitors and decreased CMPs thus 
influencing granulopoiesis [46].  Following a stress event, changes in pro-inflammatory 
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cytokines such as TNF-α, IL-1, and IL-17 (amongst others) can increase G-CSF expression [49, 
50]. The enhanced induction of G-CSF expression following pro-inflammatory cytokine 
exposure, often induced by TLR stimulation, also contributes to the PB left shift phenomenon, 
as G-CSF induces release of BM HSCs/HPCs and myeloid precursors into the blood by 
regulating surface expression of the chemokine receptor CXCR4 and production of its ligand 
CXCL12 (also known as stromal cell-derived factor-1 or SDF-1) [51-54]. The fact that G-CSF 
turns off the HSC/HPC retention signal is used in the clinic to mobilize HSCs/HPCs to the PB for 
the use in transplantations [51-54].   
Interestingly, even though TLR signaling produces a pro-inflammatory microenvironment 
that regulates G-CSF production, utilizing G-CSF as a mobilizer in MyD88 knockout mice 
resulted in enhanced HSC/HPC migration into the PB [40]. Transplantation studies revealed that 
this enhancement in HSC/HPC migration was due to cells of hematopoietic origin.  Since TLR 
activation crosstalks with activation of the complement cascade associated with innate immune 
responses and augments production of pro-inflammatory regulators [40, 55-57], it was proposed 
that one of these factors may be mechanistically involved in the altered mobilization of HSCs 
and HPCs following G-CSF administration.  MyD88 knockout BM cells, in particular, stem cell 
antigen-1 positive cells, demonstrated greatly reduced expression of heme oxygenase (HO)-1 
(a negative regulator of the complement cascade activation and a negative regulator of 
HSC/HPC mobilization) suggesting that TLR signaling enhances expression of HO-1 in 
hematopoietic cells, especially within HSC/HPC populations, resulting in the reduced migration 
of HSCs and HPCs from the BM to the blood [40, 55, 58].  This observation suggests that 
utilizing TLR antagonists may aid in enhancing G-CSF-mediated HSC/HPC mobilization.   
G-CSF plays a role in regulating hematopoiesis.  G-CSF treatment over a prolonged 
period of time in vivo can result in an initial increase in phenotyped HSC numbers.  However, 
this is followed by an increase in HSC quiescence associated with a marked decrease in HSC 
repopulating capacity [59].  Reduction of HSC function after prolonged exposure to G-CSF is 
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associated with increased TLR expression and signaling as the G-CSF-mediated alteration of 
HSC function is greatly reduced in mice lacking TLR2, TLR4 or the TLR signaling adaptor 
MyD88. These findings are further supported by the fact that prolonged exposure to G-CSF also 
can regulate TLR expression (e.g. TLR-1) and induce TLR signaling without the added 
presence of additional TLR ligands [59].  Interestingly, mice maintained under germ-free 
conditions and mice given antibiotics to suppress intestinal flora manifest reduced HSC 
dysregulation following prolonged exposure to G-CSF, suggesting that TLR stimulation is most 
likely a result of TLR ligands produced by the animal’s own microbiome [59]. Taken together, G-
CSF treatment appears to act as a stress itself, altering TLR signaling that results not only in 
changes to G-CSF treatment-induced mobilization of HSCs and HPCs, but also to HSC 
function. The role of this pharmacologically induced stress in reduction of HSC/HPC 
mobilization by mature hematopoietic components of the BM (associated with the increased 
expression of DAMPs, ROS, and proteolytic and lipolytic enzymes) has recently been reviewed 
[60**] and will not be discussed here.  However, this complicated interaction between G-CSF 
therapy and activation of TLR signaling poses a new and promising potential therapeutic target 
that deserves to be carefully explored. 
 
Chronic exposure to TLR ligand effects HSC/HPC function 
 Prolonged exposure to TLR stimulation is associated with impaired hematopoiesis [5**, 
6, 11, 38, 59].  Repeated, prolonged exposure of mice to LPS leads to increased HSC 
proliferation and an increase skewing towards myeloid cell differentiation, but is associated with 
decreased HSC repopulating capability following transplantation [36, 38].  Similarly, chronic 
exposure of mice to PAM3CSK4 led to increased HSC numbers, both in BM and spleen, but 
resulted in decreased HSC function [61].  Effects of prolonged exposure to either LPS or 
PAM3CSK4 on HSC function, however, do not appear to be linked to direct effects on HSCs or 
HPCs, but rather to increased production of pro-inflammatory stimuli such as TNF-α and G-CSF 
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[38, 61]. Negative effects to HSC function by prolonged exposure to TLR stimuli is further 
supported by the finding that prolonged exposure to cytokines/growth factors, such as the 
pharmacological administration of G-CSF, creating an environment constantly exposed to low 
doses of TLR ligands, had similar effects on HSC function [59]. However, short-term or single 
exposure to TLR agonists, as mentioned previously, resulted in increased HSC activity even 
though increased pro-inflammatory cytokine production was present [30].  These findings 
suggest that the specific effects of TLR agonists on HSC and HPC function are dependent on 
dose or duration of exposure (Figure 1).  Why short-term and long-term exposure to TLR 
agonists both resulted in increased cytokine production but have opposite effects on HSC 
function remains unclear but may represent a possible direct HSC autocrine TLR signaling 
mechanism or differential cytokine/chemokine protein or receptor production/expression.  
Understanding how this phenomenon occurs requires further investigation. 
 Accumulating evidence also suggests a role for TLRs in development of hematopoietic 
malignancies and BM failure, possibly shedding light as to how chronic stimulation of TLRs or 
aberrant TLR signaling may have detrimental effects on hematopoiesis.  TLRs have been 
associated with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, chronic 
lymphocytic leukemia, non-Hodgkin’s lymphoma, mantle cell lymphoma, and activated B-cell 
diffuse large B-cell lymphoma amongst other hematological disease [11]. Aberrant TLR 
signaling (e.g. overexpression of the TLR effector TRAF6 and the chronic activation of 
epigenetic regulators such as KDM6B) has been linked to serval lymphoproliferative disorders 
and myelodysplastic syndromes that possess a high risk of transformation to leukemia [11, 62*, 
63*]. Whether this is due to autocrine effects on HSCs and/or HPCs or the release of pro-
inflammatory cytokines that could create a microenvironment conducive to promoting 
tumorigenesis has been recently reviewed extensively [11].  
 
Conclusions 
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 There is still a lot unknown about how TLR signaling influences HSC and HPC cycling, 
differentiation and mobilization via both autocrine and paracrine mechanisms.  However, as 
more and more studies find a role for TLRs in disease progression (e.g. cancer, autoimmune 
disease, graft-versus-host disease, etc.) where targeting TLR signaling pathways through the 
use of TLR agonist or antagonist is a possible therapeutic approach, utilizing cytokines/growth 
factors as therapeutics (e.g. G-CSF) that can activate TLR signaling, or utilizing TLR agonist 
and antagonist to mitigate emergency hematopoiesis itself, it has become increasingly essential 
that we understand how these treatments might regulate HSC/HPC function [11, 40, 59, 60, 64*, 
65*, 66*, 67*, 68*].  It is possible that with a better understanding as to how TLR stimulation 
effects HSC and HPC function directly, we may be able to create better therapeutics to regulate 
hematopoiesis or alter disease progression by manipulating the hematopoietic emergency 
response to danger signals. 
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Key Points 
• TLR stimulation of HSC/HPC populations can directly affect their function both in an 
autocrine and paracrine manner leading to increased innate immune cell production of 
both myeloid and lymphoid cells. 
• Prolonged, therapeutic G-CSF therapy and other inducers of chronic TLR signaling 
negatively influence HSC function. 
• Chronic inflammatory stress and aberrant TLR signaling is associated with malignant 
hematopoietic transformation. 
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